Amuctive™ Akkermansia muciniphila
Amuc Protein Active
· Akkermansia muciniphila (AKK) is a natural occuring bacteria found in the intestinal microbiome, making up 1%-5% of the microbiome in healthy people.
· Amuctive™ Akkermansia, launched to the global market after years of R&D, represents Amuc + Active — a next-generation innovation emphasizing Akkermansia’s core active component, the Amuc_1100 protein.
Product Brief
Accumulating evidence shows Akkermansia helps maintaining the integrity of the intestinal barrier, fine-tuning the host's immune response, and enhancing multiple metabolic pathways. Compared to traditional probiotics, Akkermansia stand out as the most promising next-generation probiotic and one of the first microbes for clinical use.
Scientific Research of Akkermansia muciniphila:
· Lower Akkermansia Levels Link to Poor Health
· Regulate Postprandial Blood Glucose
· Reduces Body Obesity
· Alleviates Insulin Resistance
Scientific Researches
Lower Akkermansia Levels Link to Poor Health
Scientific research has uncovered that Akkermansia plays a beneficial role in preventing gut barrier damage and reducing insulin resistance. When the amount of Akkermansia in the gut is insufficient or has decreased, it has been associated with the occurrence of various metabolic disorder. When Akkermansia is present in the gut, it contributes to a stronger gut lining.
Moreover, it has been proven to have a positive effect on improving metabolic disorders and assisting in maintaining a healthy body weight.
American journal of physiology. Endocrinology and metabolism, 317(3), E446–E459.
Alleviates Insulin Resistance
A 3-month trial with 40 overweight volunteers with insulin resistance found that daily intake of inactivated Akkermansia (1×10¹⁰ cells/day) notably improved insulin sensitivity (+28.62±7.02%), and reduced insulinaemia (−34.08±7.12%) and total cholesterol levels (−8.68±2.38%).
Nat Med. 2019:25(7):1096-1103.
Regulate Postprandial Blood Glucose
A 12-week clinical trial involving 76 patients with type 2 diabetes (T2D) showed that daily oral intake of a five-strain formula containing Akkermansia significantly reduced postprandial glucose AUC by 36 mg/dL and HbA1c by 0.6%, with no adverse reactions reported.
BMJ Open Diabetes Res Care.2020:8(1):e001319
Reduce Body Obesity
In a clinical study of 58 overweight/obese T2D subjects, those with low baseline Akkermansia levels who received Akkermansia supplementation (1–5×10¹⁰ CFU/day) demonstrated high colonization efficiency and experienced significant reductions in body weight, fat mass, and HbA1c.
Cell Metab. 2025:3713):592-605.e6
Why Choose
Amuctive™
Comprehensive Toxicology Studies and GRAS-Certified Safety
Safety is the cornerstone of dietary ingredient development, and every efficacy must be built on a foundation of safety. To ensure this, Amuctive™ AKK has undergone systematic safety evaluations from strain selection to human clinical trials. Multiple studies have confirmed its safety and reliability, and it has been certified as SA-GRAS in the United States, ensuring peace of mind for consumers.
Market-Leading Amuc_1100 Content
Patented testing reveals Amuctive™ contains 2.5 to 7.6 times more Amuc_1100 protein than other commercial Akkermansia materials, setting a new industry standard for potency.
Robust IP Portfolio & Peer-Reviewed Research
We hold extensive patents covering Amuc_1100 content, detection methods, production processes, and efficacy. Our commitment to science is further demonstrated by ongoing publications in high-impact SCI journals.
Related Ingredients
Disclaimer *
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information is provided solely for business-to-business customers with the aim of imparting general knowledge and is not intended for end-use consumers.
Our Products
IPV4 / IPV6